Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (419)	10/4/1999 10:17:00 AM
From: jeffbas	Read Replies (2) \| Respond to of 52153

Peter, here's a perhaps dumb question that I have always wondered about, with respect to the core structure of trials. With respect to any existing disease the existing "standard of care" treatment has been through trials with known, detailed results already submitted to the FDA as to the impact on that disease of that treatment. Why spend the years of time and fortunes of dollars in doing new double-blind trials, comparing a proposed new treatment with one whose benefit is already known? Is this year's data on last year's treatment really better that last year's data on last year's treatment? Why not submit lots of data on the new treatment and let the FDA determine if it is better or not versus what they have in hand already on the existing standard of care. This way the patients who are not in the wrong 50% win, the time/cost of bringing a new treatment to market is much shorter/lower, and those of the general public who contract the disease in the meanwhile may not die. What am I missing?